• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初始化疗期间体重减轻可预测晚期胃癌患者的生存情况。

Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer.

作者信息

Takayoshi Kotoe, Uchino Keita, Nakano Masahiro, Ikejiri Koji, Baba Eishi

机构信息

a Department of Medical Oncology , Clinical Research Institute, National Hospital Organization Kyushu Medical Center , Fukuoka , Japan.

b Department of Hematology and Oncology , Kyushu University Hospital , Fukuoka , Japan.

出版信息

Nutr Cancer. 2017 Apr;69(3):408-415. doi: 10.1080/01635581.2017.1267774. Epub 2017 Jan 19.

DOI:10.1080/01635581.2017.1267774
PMID:28102709
Abstract

BACKGROUND

Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC.

METHODS

Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses.

RESULTS

The mean age of the patients was 64.4 years; 64% of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62%), fluoropyrimidine alone (26%), and other medications (12%); 72% of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss.

CONCLUSIONS

Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.

摘要

背景

晚期胃癌(AGC)患者常出现体重减轻,这可用于预测预后。很少有报告评估AGC患者化疗期间体重减轻与生存之间的相关性。

方法

对2010年9月至2014年3月开始全身化疗的53例经组织学证实的AGC患者进行回顾性研究,分析其体重、炎症状态和生存情况。进行体重变化与生存之间的相关性分析。通过逐步多元回归分析体重减轻与患者特征之间的相关性。

结果

患者的平均年龄为64.4岁;64%为男性。初始化疗包括氟嘧啶加顺铂(62%)、单纯氟嘧啶(26%)和其他药物(12%);72%的患者在初始治疗期间出现体重减轻。体重减轻高于平均值的患者的平均总生存期和平均无进展生存期比体重减轻低于平均值的患者更差。血清C反应蛋白水平与体重减轻显著相关。

结论

AGC初始化疗期间的体重减轻可能预测生存。提示全身炎症与体重减轻有关。

相似文献

1
Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer.初始化疗期间体重减轻可预测晚期胃癌患者的生存情况。
Nutr Cancer. 2017 Apr;69(3):408-415. doi: 10.1080/01635581.2017.1267774. Epub 2017 Jan 19.
2
Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer.姑息化疗第一个月时的体重减轻可预测晚期胃癌患者的生存结局。
Gastric Cancer. 2016 Apr;19(2):597-606. doi: 10.1007/s10120-015-0481-4. Epub 2015 Mar 8.
3
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.miniDOX(低剂量多西他赛-奥沙利铂-卡培他滨)用于晚期胃癌(AGC)“非最佳状态”患者的II期试验。TTD 08-02。
Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.
4
Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.奥沙利铂为基础的化疗方案治疗晚期胃癌的疗效与安全性分析
Anticancer Res. 2017 May;37(5):2663-2671. doi: 10.21873/anticanres.11614.
5
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.氟嘧啶和/或顺铂辅助治疗后复发胃癌患者多西他赛和奥沙利铂联合治疗的 II 期研究:韩国癌症研究组方案 ST06-02。
Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72. doi: 10.1007/s00280-012-1956-1. Epub 2012 Aug 25.
6
Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.多西他赛、顺铂和S-1三联化疗难治的晚期胃癌中紫杉烷单药治疗的疗效和安全性:一项多中心回顾性研究
Cancer Chemother Pharmacol. 2017 Sep;80(3):575-582. doi: 10.1007/s00280-017-3397-3. Epub 2017 Jul 20.
7
Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.铂类双联化疗用于伴弥散性血管内凝血的晚期胃癌
Anticancer Res. 2017 Jan;37(1):309-313. doi: 10.21873/anticanres.11322.
8
Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination.对45例连续接受S-1/顺铂联合新辅助化疗的晚期胃癌患者进行回顾性分析。
Gastric Cancer. 2006;9(2):129-35. doi: 10.1007/s10120-006-0369-4.
9
Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.血清HER2胞外区对接受曲妥珠单抗联合化疗的HER2阳性晚期胃癌患者的预测价值
J Gastroenterol. 2015 Sep;50(9):955-61. doi: 10.1007/s00535-015-1046-3. Epub 2015 Feb 22.
10
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.S-1单药治疗难治的晚期胃癌患者二线伊立替康联合顺铂与单用伊立替康的随机III期试验:TRICS试验
Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18.

引用本文的文献

1
Visceral adipose tissue in the lesser omentum predicts lymphovascular invasion, perineural invasion and survival in gastric cancer.小网膜内的内脏脂肪组织可预测胃癌的淋巴管侵犯、神经周围侵犯及生存情况。
Front Oncol. 2025 Jun 19;15:1555824. doi: 10.3389/fonc.2025.1555824. eCollection 2025.
2
Synergistic Strategies for Gastrointestinal Cancer Care: Unveiling the Benefits of Immunonutrition and Microbiota Modulation.协同策略在胃肠道癌症治疗中的应用:免疫营养与微生物群调节的益处。
Nutrients. 2023 Oct 17;15(20):4408. doi: 10.3390/nu15204408.
3
Physical Resilience as a Predictor of Lifespan and Late-Life Health in Genetically Heterogeneous Mice.
生理弹性作为遗传异质小鼠寿命和老年健康的预测指标。
J Gerontol A Biol Sci Med Sci. 2024 Jan 1;79(1). doi: 10.1093/gerona/glad207.
4
Yiqi Chutan Formula Reverses Cisplatin-Induced Apoptosis and Ferroptosis of Skeletal Muscle by Alleviating Oxidative Stress.益气除痰方通过减轻氧化应激逆转顺铂诱导的骨骼肌细胞凋亡和铁死亡。
Integr Cancer Ther. 2023 Jan-Dec;22:15347354231172117. doi: 10.1177/15347354231172117.
5
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.体重减轻作为转移性胃癌既往治疗患者的预后和预测因素:随机 III 期 TAGS 试验的事后分析。
Gastric Cancer. 2023 Jul;26(4):626-637. doi: 10.1007/s10120-023-01393-2. Epub 2023 Apr 28.
6
Effects of Voluntary Wheel Running Exercise on Chemotherapy-Impaired Cognitive and Motor Performance in Mice.自愿转轮运动对化疗损伤的小鼠认知和运动表现的影响。
Int J Environ Res Public Health. 2023 Apr 3;20(7):5371. doi: 10.3390/ijerph20075371.
7
Preoperative High Visceral Fat Increases Severe Complications but Improves Long-Term Prognosis after Gastrectomy for Patients with Advanced Gastric Cancer: A Propensity Score Matching Analysis.术前高内脏脂肪增加胃癌患者胃切除术后严重并发症但改善长期预后:倾向评分匹配分析。
Nutrients. 2022 Oct 11;14(20):4236. doi: 10.3390/nu14204236.
8
A preponderance of gastrointestinal cancer patients transition into cachexia syndrome.大量胃肠道癌患者发展为恶病质综合征。
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2920-2931. doi: 10.1002/jcsm.13086. Epub 2022 Sep 27.
9
Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.肿瘤细胞合成代谢与宿主组织分解代谢-癌症恶病质期间的能量效率低下。
Exp Biol Med (Maywood). 2022 May;247(9):713-733. doi: 10.1177/15353702221087962. Epub 2022 May 6.
10
Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies.早期体重减轻作为晚期胃癌患者的预后因素:来自REGARD、RAINBOW和RAINFALL三期研究的分析
Oncologist. 2021 Sep;26(9):e1538-e1547. doi: 10.1002/onco.13836. Epub 2021 Jun 9.